Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice

Cancer Research

Volumn 64, Issue 12, 2004, Pages 4201-4208

  Kim, Sun Jin ^a   Uehara, Hisanori ^a   Yazici, Sertac ^a   Langley, Robert R ^a   He, Junqin ^a   Tsan, Rachel ^a   Fan, Dominic ^a   Killion, Jerald J ^a   Fidler, Isaiah J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; EPIDERMAL GROWTH FACTOR RECEPTOR; IMATINIB; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE METASTASIS; BONE STRUCTURE; BONE TISSUE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; ENDOTHELIUM CELL; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; TUMOR CELL; TUMOR GROWTH;

ANIMALS; ANTIGENS, CD31; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BONE NEOPLASMS; CELL DIVISION; ENZYME INHIBITORS; HUMANS; IN SITU NICK-END LABELING; MALE; MICE; MICE, NUDE; PACLITAXEL; PHOSPHORYLATION; PIPERAZINES; PROSTATIC NEOPLASMS; PYRIMIDINES; PYRROLES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SUBSTRATE SPECIFICITY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 3042523539     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-3763     Document Type: Article

References (82)

1. Landis SH, Murray T, Bolden-Wingo PA. Cancer statistics, 1999. Cancer (Phila) 1999;49:8-31.
2. Soh S, Kattan MW, Berkman S, Wheeler TM, Scardino PT. Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy? J. Urol 1997;157:2212-8.
3. Barrettoni BA, Carter JR. Mechanisms of cancer metastasis to bone. J Bone Joint Surg Am 1986;68A:308-12.
4. Jacobs SC. Spread of prostatic cancer to bone. Urology 1983;21:337-44.
5. Fidler IJ. Critical factors in the biology of human cancer metastasis: twenty-eighth G. H. A. Clowes Memorial Award lecture. Cancer Res 1990;50:6130-8.
6. Grignon DJ, Hammond EH. College of American Pathologists Conference XXVI on Clinical Relevance of Prognostic Markers in Solid Tumors: report of the Prostate Cancer Working Group. Arch Pathol Lab Med 1995;119:1122-6.
7. Sgrinoli AR, Walsh PC, Steinberg GD, Steiner MS, Epstein JI. Prognostic factors in men with stage D1 prostate cancer: identification of patients less likely to have prolonged survival after radical prostatectomy. J Urol 1994;152:1077-81.
8. Partin AW, Yoo J, Bellentine CH, et al. The use of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1994;150:110-4.
9. Fidler IJ. Modulation of the organ microenvironment for the treatment of cancer metastasis. J Natl Cancer Inst (Bethesda) 1995;87:1588-92.
10. Fidler IJ, Radinsky R. Genetic control of cancer metastasis. J Natl Cancer Inst (Bethesda) 1990;82:166-8.
11. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889;1:571-3.
12. Kim SJ, Uehara H, Karashima T, Shepherd DL, Killion JJ, Fidler IJ. Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Clin Cancer Res 2003;9:1200-10.
13. Uehara H, Kim SJ, Karashima T, et al. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst (Bethesda) 2003;95:558-70.
14. Ulrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990;61:203-12.
15. Yarden Y, Ulrich A. Growth factor receptor tyrosine kinases. Annu Rev Biochem 1988;57:443-78.
16. Wells A. EGF receptor. Int J Biochem Cell Biol 1999;31:637-43.
17. Uhlman DL, Nguyen P, Manivel JC, et al. Epidermal growth factor receptor and transforming growth factor-α expression in papillary and nonpapillary renal cell carcinoma: correlation with metastatic behavior and prognosis. Clin Cancer Res 1995;8:913-20.
18. Atlas I, Mendelsohn J, Baselga J, Fair WR, Masui H, Kumar R. Growth regulation of human renal carcinoma cells: role of transforming growth factor-α. Cancer Res 1992;52:3335-9.
19. Moch H, Sautter G, Buchholz N, et al. Epidermal growth factor receptor expression is associated with rapid tumor cell proliferation in renal cell carcinoma. Hum Pathol 1997;11:1255-9.
20. Hofmockel G, Riess S, Bassukas ID, Dammrich J. Epidermal growth factor family and renal cell carcinoma: expression and prognostic impact. Eur Urol 1997;4:478-84.
21. Yoshida K, Tosaka A, Takeuchi S, Kobayashi N. Epidermal growth factor receptor content in human renal cell carcinomas. Cancer (Phila) 1994;73:1913-8.
22. Xie J, Aszterbaum M, Zhang X, et al. A role of PDGF-Rβ in basal cell carcinoma proliferation. Proc Natl Acad Sci USA 2001;98:9255-9.
23. Funa K, Papanicolaou V, Juhlin C, et al. Expression of platelet-derived growth factor alpha-receptois on stromal tissue cells in human carcinoid tumors. Cancer Res 1990;50:748-53.
24. Liu YC, Chen SC, Chang C, Leu CM, Hu CP. Platelet-derived growth factor is an autocrine stimulator for the growth and survival of human esophageal carcinoma cell lines. Exp Cell Res 1996;228:206-11.
25. Bornfeldt KE, Raines EW, Nakano T, Graves LM, Krebs EG, Ross R. Insulin-like growth factor-I and platelet-derived growth factor-BB induce directed migration of human arterial smooth muscle cells via signaling pathways that are distinct from those of proliferation J Clin Investig 1994;93:1266-74.
26. Plate KH, Breier G, Farrell CL, Risau W. Platelet-derived growth factor receptor-β is induced during tumor development and upregulated during tumor progression in endothelial cells in human gliomas. Lab Investig 1992;67:529-34.
27. Zhang SX, Gozal D, Sachleben LR Jr, Rane M, Klein JB, Gozal E. Hypoxia induces on autocrine-paracrine survival pathway via platelet-derived growth factor (PDGF)-β/PDGF-β receptor/phosphatidylinositol 3-kinase/Akt signaling in RN46A neuronal cells. FASEB J 2003;17:1709-11.
28. Traxler P, Bold G, Buchdunger E, et al. Tyrosine kinase inhibitors: from rational design to clinical trials. Med Res Rev 2001;21:499-512.
29. Druker, BJ, Tamura S, Buchdunger E, et al. Effects of selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6.
30. McCormick F. New-age drug meets resistance. Nature (Lond) 2001;412:281-2.
31. Pettaway CA, Pathak S, Greene G, et al. Selection of highly metastatic variants of different human prostate carcinomas utilizing orthotopic implantation in nude mice. Clin Cancer Res 1996;2:1627-36.
32. Morris S, Sawai T, Teshima T, Kyogoku M. A new decalcifying technique for immunohistochemical studies of calcified tissue, especially applicable to cell surface marker demonstration. J Histochem Cytochem 1988;36:111-4.
33. Russ JC. The image processing handbook, 2nd ed. Boca Raton, FL: CRC Press, 1995. p. 463-9.
34. Fidler IJ, Yano S, Zhang R, Fujimaki T, Bucana CD. The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol 2002;3:53-7.
35. Bruns CJ, Solorzano CC, Harbison MT, et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 2000;60:2926-35.
36. Folkman MJ. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992;3:65-71.
37. Baker CH, Kedar D, McCarty MF, et al. Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas. Am J Pathol 2002;161:929-38.
38. Hou X, Johnson AC, Rosner MR. Induction of epidermal growth factor receptor gene transcription by transforming growth factor beta 1: association with loss of protein binding to a negative regulatory element. Cell Growth Differ 1994;5:801-9.
39. Saha D, Datta PK, Sheng H, et al. Synergistic induction of cyclooxygenase-2 by transforming growth factor-β1 and epidermal growth factor inhibits apoptosis in epithelial cells. Neoplasia 1999;1:508-17.
40. Vinals F, Pouyssegur J. Transforming growth factor (TGF)-β1 promotes endothelial cell survival during in vitro angiogenesis via an autocrine mechanism implicating TGF-α signaling. Mol Cell Biol 2001;21:7218-30.
41. Soory M, Virdi H. Implications of minocycline, platelet-derived growth factor, and transforming growth factor-β on inflammatory repair potential in the periodontium. J Periodontol 1999;70:1136-43.
42. Seifert RA, Coats SA, Raines EW, Ross R, Bowen-Pope DF. Platelet-derived growth factor (PDGF)-receptor α-subunit mutant and reconstituted cell lines demonstrate that transforming growth factor-β can be mitogenic through PDGF A-chain-dependent and -independent pathways. J Biol Chem 1994;269:13951-5.
43. Lorenzo GD, Tortora G, D'Armiento FP, et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 2002;8:3438-44.
44. Fudge K, Bostwick DG, Stearns ME. Platelet-derived growth factor A and B chains and α and β receptors in prostatic intraepithelial neoplasia. Prostate 1996;29:282-6.
45. Fujimura M, Hidaka T, Saito S. Selective inhibition of the epidermal growth factor receptor by ZD1839 decreases the growth and invasion of ovarian clear cell adenocarcinoma cells. Clin Cancer Res 2002;8:2448-54.
46. Henriksen R, Funa K, Wilander E, Backstrom T, Ridderheim M, Oberg K. Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res 1993;53:4550-4.
47. Mukohara T, Kudoh S, Yamauchi S, et al. Expression of epidermal growth factor-receptor (EGF-R) and downstream-activated peptides in surgically excised non-small-cell lung cancer (NSCLC). Lung Cancer 2003;41:123-30.
48. Antoniades HN, Galanopoulos T, Neville-Golden J, O'Hara CJ. Malignant epithelial cells in primary human lung carcinomas coexpress in vivo platelet-derived growth factor (PDGF) and PDGF-receptor mRNAs and their protein products. Proc Natl Acad Sci USA 1992;89:3942-6.
49. Layfield LJ, Bernard PS, Goldstein NS. Color multiplex polymerase chain reaction for quantitative analysis of epidermal growth factor receptor genes in colorectal adenocarcinoma. J Surg Oncol 2003;83:227-31.
50. Lindmark G, Sundberg C, Glimelius B, Pahlman L, Rubin K, Gerdin B. Stromal expression of platelet-derived growth factor beta-receptor and platelet-derived growth factor B-chain in colorectal cancer. Lab Investig 1993;69:682-9.
51. García I, Vizoso F, Martin A, et al. Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol 2003;10:234-41.
52. Chung CK, Antoniades HN. Expression of c-sis/platelet-derived growth factor B, insulin-like growth factor I, and transforming growth factor-α messenger RNAs and their respective receptor messenger RNAs in primary human gastric carcinomas: in vivo studies with in situ hybridization and immunocytochemistry. Cancer Res 1992; 52:3453-9.
53. Friess H, Fukuda A, Tang WH, et al. Concomitant analysis of the epidermal growth factor receptor family in esophageal cancer: overexpression of epidermal growth factor receptor mRNA but not of c-erbB-2 and c-erbB-3. World J Surg 1999;23:1010-8.
54. Yoshida K, Kuniyasu H, Yasui W, Kitadai Y, Toge T, Tahara E. Expression of growth factors and their receptors in human esophageal carcinomas: regulation of expression by epidermal growth factor and transforming growth factor alpha. J Cancer Res Clin Oncol 1992;119:401-7.
55. Tsutsui S, Ohno S, Murakami S, Kataoka A, Kinoshita J, Hachitanda Y. Prognostic significance of the combination of biological parameters in breast cancer. Surg Today 2003;33:151-4.
56. Seymour L, Dajee D, Bezwoda WR. Tissue platelet derived-growth factor (PDGF) predicts for shortened survival and treatment failure in advanced breast cancer. Breast Cancer Res Treat 1993;26:247-52.
57. Zhou YH, Tan F, Hess KR, Yung WK. The Expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor-receptor in gliomas: relationship to tumor grade and survival. Clin Cancer Res 2003;9:3369-75.
58. Hermanson M, Funa K, Koopmann J, et al. Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor alpha-receptor expression in human malignant gliomas. Cancer Res 1996;56:164-71.
59. de Wit PE, Moretti S, Koenders PG, et al. Increasing epidermal growth factor receptor expression in human melanocytic tumor progression. J Investig Dermatol 1992;99:168-73.
60. Palumbo C, van Roozendaal K, Gillis AJ, et al. Expression of the PDGFα-receptor 1.5 kb transcript, OCT-4, and c-KIT in human normal and malignant tissues: implications for the early diagnosis of testicular germ cell tumors and for our understanding of regulatory mechanisms. J Pathol 2002;196:467-77.
61. Levitzki A. Tyrosine kinases as targets for cancer therapy. Eur J Cancer 2002; 38(Suppl 5):S11-8.
62. Laird AD, Cherrington JM. Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents. Expert Opin Investig Drugs 2003;12:51-64.
63. Ghosh S, Liu XP, Zheng Y, Uckun FM. Rational design of potent and selective EGF-R tyrosine kinase inhibitors as anticancer agents. Curr Cancer Drug Targets 2001;1:129-40.
64. Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002;1:493-502.
65. Manley PW, Cowan-Jacob SW, Buchdunger E, et al. Imatinib: a selective tyrosine kinase inhibitor. Eur J Cancer 2002;38(Suppl 5):S19-27.
66. Ulrich A, Coussens L, Hayflick JS, et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature (Lond) 1984;309:418-25.
67. Ciardiello F, Damiano V, Bianco R, et al. Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. J Natl Cancer Inst (Bethesda) 1996;88:1770-6.
68. Uckun FM, Narla RK, Zeren T, et al. In vivo toxicity, pharmacokinetics, and anticancer activity of Genistein linked to recombinant human epidermal growth factor. Clin Cancer Res 1988;4:1125-34.
69. Uckun FM, Narla RK, Jun X, et al. Cytotoxic activity of epidermal growth factor-genistein against breast cancer cells. Clin Cancer Res 1988;4:901-12.
70. Thyberg J. The microtubular cytoskeleton and the initiation of DNA synthesis. Exp Cell Res 1984;155:1-8.
71. Yoon SY, Tefferi A, Li CY. Cellular distribution of platelet-derived growth factor, transforming growth factor-β, basic fibroblast growth factor, and their receptors in normal bone marrow. Acta Haematol 2000;104:151-7.
72. Marcoux N, Vuori K. EGF receptor mediates adhesion-dependent activation of the Rac GTPase: a role for phosphatidylinositol 3-kinase and Vav2. Oncogene 2003;22:6100-6.
73. Pietras K, Ostman A, Sjoquist M, et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001;61:2929-34.
74. Heuchel R, Berg A, Tallquist M, et al. Platelet-derived growth factor beta-receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3′ kinase signaling. Proc Natl Acad Sci USA 1999;96:11410-5.
75. Yano S, Nishioka Y, Goto H, Sone S. Molecular mechanisms of angiogenesis in non-small cell lung cancer, and therapeutics targeting related molecules. Cancer Sci 2003;94:479-85.
76. Suhardja A, Hoffman H. Role of growth factors and their receptors in proliferation of microvascular endothelial cells. Microsc Res Tech 2003;60:70-5.
77. Cao R, Brakenhielm E, Li X, et al. Angiogenesis stimulated by PDGF-CC, a novel member in the PDGF family, involves activation of PDGF-AA and -AB receptors. FASEB J 2002;16:1575-83.
78. Battegay EJ, Rupp J, Iruela-Arispe L, Sage EH, Pech M. PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGFβ-receptors. J Cell Biol 1994;125:917-28.
79. Morioka H, Weissbach L, Vogel T, et al. Anti-angiogenesis treatment combined with chemotherapy produces chondrosarcoma necrosis. Clin Cancer Res 2003;9:1211-7.
80. Saharinen P, Alitalio K. Double target for tumor mass destruction. J Clin Investig 2003;111:1277-80.
81. Aimakajornboon N, Szerlip NJ, Gozal E, Anonetapipat JH, Gozal D. In vivo PDGFβ receptor activation in the dorsocaudal brain stem of the rat prevents hypoxia-induced apoptosis via activation of Akt and Bad Brain Res 2001;895:111-8.
82. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 2000;60:1388-93.